Phase II evaluation of the sulfonylurea LY186,641 in men with hormone independent metastatic prostate cancer.
Wilding
G
G
Department of Human Oncology, University of Wisconsin Comprehensive Cancer Center, Madison.
Grindey
G
G
Munshi
N
N
Seitz
D
D
Einhorn
L
L
D000284:Administration, Oral; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000556:secondary; D006801:Humans; D008297:Male; D009367:Neoplasm Staging; D009376:Neoplasms, Hormone-Dependent / Q000188:drug therapy*; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D012983:Soft Tissue Neoplasms / Q000556:secondary; D013453:Sulfonylurea Compounds / Q000009:adverse effects / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D013453:Sulfonylurea Compounds; C058179:sulofenur